05 — Raleigh-Durham, North Carolina, USA.

TGNA Foresight Score: 78 · ▲ Ascending

The signal: The Research Triangle has attracted $10.8 billion in life sciences investment and over 4,500 new jobs in 2024 alone with Duke, UNC-Chapel Hill, and NC State converting decades of research output into one of the most productive biotech and AI commercialization corridors.

Signs: Duke University, UNC Chapel Hill, and NC State form one of the most concentrated research ecosystems in North America. Biotech lab space absorption has increased steadily since 2021, with global pharmaceutical firms expanding operations in the region.

Events: Novartis announced a $771 million expansion in 2025, creating over 700 biologics jobs in Durham and Wake counties by 2030. Genentech broke ground on a $700 million advanced manufacturing facility in Holly Springs focused on next-generation obesity treatments. In 2025, 18 life sciences companies announced expansions in North Carolina totaling $3.79 billion and 1,380 new jobs.

Trends: Raleigh-Durham has spent the last decade quietly displacing legacy biotech markets not by competing on reputation, but by delivering lower costs and a workforce pipeline that Boston and San Francisco can no longer match on price. Lab space has more than doubled since 2016 and capital keeps arriving.

Drivers: Three tier-one research universities feeding a commercialization pipeline that no policy decision can replicate overnight, a cost structure that makes Boston and San Francisco look inefficient, and a state government that has treated life sciences as a generational priority. That combination is why capital keeps coming back.

Federico Quinzaños

Founder - The Grand North America